Aspire Private Capital’s Freeline Therapeutics Holdings FRLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-80
Closed -$509 – 760
2023
Q4
$509 Hold
80
– – ﹤0.01% 642
2023
Q3
$344 Hold
80
– – ﹤0.01% 651
2023
Q2
$206 Hold
80
– – ﹤0.01% 648
2023
Q1
$546 Hold
80
– – ﹤0.01% 599
2022
Q4
$570 Hold
80
– – ﹤0.01% 588
2022
Q3
$1K Hold
80
– – ﹤0.01% 600
2022
Q2
$1K Hold
80
– – ﹤0.01% 591
2022
Q1
$1K Buy
+80
New +$1.48K ﹤0.01% 585

Aspire Private Capital's FRLN Position: Q1 2024 in Review

Aspire Private Capital sold out of Freeline Therapeutics Holdings (FRLN) in Q1 2024, closing a stake of 80 shares — an estimated $509 sold.

Aspire Private Capital first reported a position in FRLN in Q1 2022 and held it in 8 quarters. The position peaked at $1K in Q3 2022. 0 funds tracked by Wall St. Rank hold FRLN as of Q1 2024.

  • Aspire Private Capital reported no remaining Freeline Therapeutics Holdings position as of Q1 2024 after selling out during the quarter.
  • Aspire Private Capital sold 80 Freeline Therapeutics Holdings shares in Q1 2024, an estimated $509.
  • Aspire Private Capital first reported a position in Freeline Therapeutics Holdings in Q1 2022 and held it in 8 quarters.
  • Aspire Private Capital's Freeline Therapeutics Holdings position peaked at $1K in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings as of Q1 2024.

Based on Aspire Private Capital's 13F filing for Q1 2024, filed 18 Apr 2024.